Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists

REFERENCES

• Barnett, B. S., W. O. Siu, and H. G. Pope. 2018. A survey of American psychiatrists’ attitudes toward classic hallucinogens. The Journal of Nervous and Mental Disease 206 (6):476–80. doi:10.1097/NMD.0000000000000828.
   PubMed Web of Science ®Google Scholar
• Belouin, S. J., and J. E. Henningfield. 2018. Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology 142:7–19. doi:10.1016/j.neuropharm.2018.02.018.
   PubMed Web of Science ®Google Scholar
• Cabrera, L. Y., N. S. Fitz, and P. B. Reiner. 2015. Empirical support for the moral salience of the therapy-enhancement distinction in the debate over cognitive, affective and social enhancement. Neuroethics 8 (3):243–56. doi:10.1007/s12152-014-9223-2.
   Web of Science ®Google Scholar
• Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, and D. J. Nutt. 2021. Trial of psilocybin versus escitalopram for depression. The New England Journal of Medicine 384 (15):1402–11. doi:10.1056/NEJMoa2032994.
   PubMed Web of Science ®Google Scholar
• Cheung, K., B. D. Earp, and D. B. Yaden. 2024. Valuing the acute subjective experience. Perspectives in Biology and Medicine. Online ahead of print. https://www.researchgate.net/publication/376756766_Valuing_the_Acute_Subjective_Experience
   Google Scholar
• Cheung, K., K. Patch, B. D. Earp, and D. B. Yaden. 2023. Psychedelics, meaningfulness, and the “proper scope” of medicine: Continuing the conversation. Cambridge Quarterly of Healthcare Ethics. Online ahead of print. doi:10.1017/S0963180123000270.
   PubMedGoogle Scholar
• Corrigan, K., M. Haran, C. McCandliss, R. McManus, S. Cleary, R. Trant, Y. Kelly, K. Ledden, G. Rush, V. O'Keane, et al. 2022. Psychedelic perceptions: Mental health service user attitudes to psilocybin therapy. Irish Journal of Medical Science 191 (3):1385–97. doi:10.1007/s11845-021-02668-2.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., G. Agin-Liebes, M. España, B. Pilecki, and J. Luoma. 2022. Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. Journal of Psychoactive Drugs 54 (4):309–18. doi:10.1080/02791072.2021.1971343.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., F. S. Barrett, D. G. May, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, P. H. Finan, and R. R. Griffiths. 2021. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78 (5):481–9. doi:10.1001/jamapsychiatry.2020.3285.
   PubMed Web of Science ®Google Scholar
• de Laportalière, T. T., A. Jullien, A. Yrondi, P. Cestac, and F. Montastruc. 2023. Reporting of harms in clinical trials of esketamine in depression: A systematic review. Psychological Medicine 53 (10):4305–15. doi:10.1017/S0033291723001058.
   PubMed Web of Science ®Google Scholar
• Earp, B. D., J. Lewis, V. Dranseika, and I. R. Hannikainen. 2021. Experimental philosophical bioethics and normative inference. Theoretical Medicine and Bioethics 42 (3–4):91–111. doi:10.1007/s11017-021-09546-z.
   PubMed Web of Science ®Google Scholar
• Earp, B. D., J. Lewis, and C. L. Hart, and Bioethicists and Allied Professionals for Drug Policy Reform. 2021. Racial justice requires ending the war on drugs. The American Journal of Bioethics 21 (4):4–19. doi:10.1080/15265161.2020.1861364.
   PubMed Web of Science ®Google Scholar
• Evans, J., O. C. Robinson, E. K. Argyri, S. Suseelan, A. Murphy-Beiner, R. McAlpine, D. Luke, K. Michelle, and E. Prideaux. 2023. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLOS One 18 (10):e0293349. doi:10.1371/journal.pone.0293349.
   PubMed Web of Science ®Google Scholar
• Fitz, N. S., R. Nadler, P. Manogaran, E. W. J. Chong, and P. B. Reiner. 2014. Public attitudes toward cognitive enhancement. Neuroethics 7 (2):173–88. doi:10.1007/s12152-013-9190-z.
   Web of Science ®Google Scholar
• Gandy, S. 2019. Psychedelics and potential benefits in “healthy normals”: A review of the literature. Journal of Psychedelic Studies 3 (3):280–7. doi:10.1556/2054.2019.029.
   Google Scholar
• Goodwin, G. M., S. T. Aaronson, O. Alvarez, P. C. Arden, A. Baker, J. C. Bennett, C. Bird, R. E. Blom, C. Brennan, D. Brusch, et al. 2022. Single-dose psilocybin for a treatment-resistant episode of major depression. The New England Journal of Medicine 387 (18):1637–48. doi:10.1056/NEJMoa2206443.
   PubMed Web of Science ®Google Scholar
• Graham, J., J. Haidt, and B. A. Nosek. 2009. Liberals and conservatives rely on different sets of moral foundations. Journal of Personality and Social Psychology 96 (5):1029–46. doi:10.1037/a0015141.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., W. A. Richards, U. McCann, and R. Jesse. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187 (3):268–83. doi:10.1007/s00213-006-0457-5.
   PubMed Web of Science ®Google Scholar
• Hart, C. L. 2020. Exaggerating harmful drug effects on the brain is killing black people. Neuron 107 (2):215–8. doi:10.1016/j.neuron.2020.06.019.
   PubMed Web of Science ®Google Scholar
• Ioannidis, J. P. 2023. Medical necessity under weak evidence and little or perverse regulatory gatekeeping. Clinical Ethics 18 (3):330–4. doi:10.1177/14777509231169898.
   Google Scholar
• Jacobs, A. 2023. Legal use of hallucinogenic mushrooms begins in Oregon. The New York Times, January 3.
   Google Scholar
• Jacobsen, H. B., A. Stubhaug, B. Holmøy, T. M. Kvam, and S. E. Reme. 2021. Have Norwegians tried psilocybin, and do they accept it as a medicine? Journal of Psychedelic Studies 5 (1):33–6. doi:10.1556/2054.2021.00167.
   Google Scholar
• Johnson, M., W. Richards, and R. Griffiths. 2008. Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology 22 (6):603–20. doi:10.1177/0269881108093587.
   PubMed Web of Science ®Google Scholar
• Lewis, J., B. D. Earp, and C. L. Hart. 2022. Pathways to drug liberalization: racial justice, public health, and human rights. The American Journal of Bioethics: Ajob 22 (9):W10–W12. doi:10.1080/15265161.2021.1940370.
   PubMed Web of Science ®Google Scholar
• Lutkajtis, A., and J. Evans. 2023. Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands. Journal of Psychedelic Studies 6 (3):211–21. doi:10.1556/2054.2022.00232.
   Google Scholar
• Mennis, J., G. J. Stahler, and M. J. Mason. 2021. Treatment admissions for opioids, cocaine, and methamphetamines among adolescents and emerging adults after legalization of recreational marijuana. Journal of Substance Abuse Treatment 122:108228. doi:10.1016/j.jsat.2020.108228.
   PubMed Web of Science ®Google Scholar
• Mihailov, E., B. Rodríguez López, F. Cova, and I. R. Hannikainen. 2021. How pills undermine skills: Moralization of cognitive enhancement and causal selection. Consciousness and Cognition 91:103120. doi:10.1016/j.concog.2021.103120.
   PubMed Web of Science ®Google Scholar
• Sabini, J., and J. Monterosso. 2005. Judgments of the fairness of using performance enhancing drugs. Ethics & Behavior 15 (1):81–94. doi:10.1207/s15327019eb1501_6.
   PubMed Web of Science ®Google Scholar
• Savulescu, J., C. Gyngell, and G. Kahane. 2021. Collective reflective equilibrium in practice (CREP) and controversial novel technologies. Bioethics 35 (7):652–63. doi:10.1111/bioe.12869.
   PubMed Web of Science ®Google Scholar
• Schlag, A. K., J. Aday, I. Salam, J. C. Neill, and D. J. Nutt. 2022. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology 36 (3):258–72. doi:10.1177/02698811211069100.
   PubMed Web of Science ®Google Scholar
• Stegenga, J. 2018. Medical nihilism. Oxford: Oxford University Press.
   Google Scholar
• van Elk, M., and E. I. Fried. 2023. History repeating: guidelines to address common problems in psychedelic science. Therapeutic Advances in Psychopharmacology 13:20451253231198466. doi:10.1177/20451253231198466.
   Web of Science ®Google Scholar
• Wang, K. Y., B. Sun, L. Nava, R. J. Sampiere, and K. P. Jacobs. 2023. Predictors of medical students’ perceptions of psilocybin-assisted therapy for use in medical practice. Cureus 15 (4):e37450. doi:10.7759/cureus.37450.
   PubMed Web of Science ®Google Scholar
• Wildberger, J. I., C. N. John, and R. M. Hallock. 2017. Perceptions of the medicinal value of hallucinogenic drugs among college students. Journal of Psychedelic Studies 1 (2):50–4. doi:10.1556/2054.01.2017.008.
   Google Scholar
• Yaden, D. B., B. D. Earp, and R. R. Griffiths. 2022. Ethical issues regarding nonsubjective psychedelics as standard of care. Cambridge Quarterly of Healthcare Ethics 31 (4):464–71. doi:10.1017/S096318012200007X.
   PubMed Web of Science ®Google Scholar
• Yaden, D. B., J. B. Potash, and R. R. Griffiths. 2022. Preparing for the bursting of the psychedelic hype bubble. JAMA Psychiatry 79 (10):943–4. doi:10.1001/jamapsychiatry.2022.2546.
   PubMed Web of Science ®Google Scholar